Homburger advised 21Shares on the issuance and listing of its Dogecoin-linked Exchange Traded Product (DOGE) on the SIX Swiss Exchange. The context The issuance in question is linked to and fully physically collateralized by Dogecoin
Tags :sx1
Homburger advised New Zealand Local Government Funding Agency (LGFA) in connection with its debut issuance under its EMTN Programme, marking the the agency’s first issuance in CHF. UBS Investment Bank and BNP Paribas (Suisse) &
Walder Wyss advised Swiss Life on a EUR 500 million senior bond placement. In connection with the operation, Homburger represented BNP Paribas, J.P. Morgan, Natixis and UBS Europe, acting as joint lead managers. Moreover, UBS
Swiss biotechnology company Araris Biotech completed its sale to Taiho Pharmaceutical. In connection with the deal BGPartner advised Araris on all Swiss legal matters, while Baker McKenzie represented the company with regard to all Swiss
Baker McKenzie advised Swiss 3D simulation technology specialist Crisalix and its shareholders on its acquisition by Hamburg-based investment firm BID Equity. The context BID Equity’s focus lays on creating value through buy and build
Baker McKenzie advised The Bastion Collection, owner of The Woodward hotel in Geneva, on the hotel management transition from Oetker Collection to Auberge Resorts Collection and the respective negotiation of a new hotel management agreement.
Homburger advised Berlin-based HR Group on its acquisition of German privately managed hotel company H-Hotels. The context HR Group’s activity spans acquiring, developing, and operating hotels and resorts. Pursuant to the transaction, the group
Niederer Kraft Frey (NKF) advised Muttenz-based Clariant on the placement of two CHF bond trances: Tranche A amounts CHF 125 million and has a term to maturity of three years, while Trance B is a
Zurich-based fintech AMNIS completed a CHF 10 million series B financing round. Swisscom Ventures led the capital round in question, which saw the participation of existing investors – including co-investor Lansdowne. The operation also encompasses a CHF 2
Niederer Kraft Frey (NKF) advised AB2 Bio, a Swiss biotechnology company, on Swiss law matters in connection with the entry into an option and licensing agreement with Japanese pharmaceutical company Nippon Shinyaku. The context Headquartered
